Sign Up Today and Learn More About CRISPR Therapeutics Stock

Invest in or calculate the value of your shares in CRISPR Therapeutics or other pre-IPO companies through EquityZen's platform.

Get Started

CRISPR Therapeutics Stock

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform.

About CRISPR Therapeutics Stock

Founded

2013

Headquarters

Cambridge, MA, US

Total Funding

127M

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.

CRISPR Therapeutics Press Mentions

Stay in the know about the latest news on CRISPR Therapeutics

CRISPR Therapeutics Management

Leadership team at CRISPR Therapeutics

Scientific Founders

Daniel Anderson

Scientific Founders

Emmanuelle Charpentier

Locked Features

Join now and verify your accreditation status to gain access to:

  • CRISPR Therapeutics current valuation
  • CRISPR Therapeutics stock price
  • Available deals in CRISPR Therapeutics and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in CRISPR Therapeutics stock?

Accredited investors can buy pre-IPO stock in companies like CRISPR Therapeutics through EquityZen funds. These investments are made available by existing CRISPR Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell CRISPR Therapeutics stock?

Shareholders can sell their CRISPR Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 300K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 41K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."